Physician profile
Dan Tang
NPI 1992990394
$5,089.91
in general payments reported to CMS, 2019-2025
38 companies · $78.49 in 2025
The $78.49 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,011 · 2020: $525 · 2021: $623 · 2022: $805 · 2023: $1,014 · 2024: $1,034 · 2025: $78.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,107 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,106.54 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $882.69 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $519.56 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $451.63 | 2019-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $305.31 | 2019-2023 | Tradjenta, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $285.39 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $282.73 | 2019-2023 | |
| Antares Pharma, INC. | $246.25 | 2020-2024 | Xyosted, Nocdurna, Tlando |
| Xeris Pharmaceuticals, INC. | $231.20 | 2021-2024 | Recorlev, Gvoke Hypopen |
| Mannkind Corporation | $208.51 | 2020-2024 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $207.95 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $133.81 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $133.19 | 2022-2023 | Strensiq |
| Abbvie INC. | $127.99 | 2019-2024 | Synthroid |
| Corcept Therapeutics | $122.54 | 2019-2024 | Korlym |
| Dexcom, INC. | $94.24 | 2019-2024 | Dexcom G6 Transmitter |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $74.56 | 2023-2024 | |
| Lifescan, INC. | $68.84 | 2019 | |
| Medtronic, INC. | $65.12 | 2022-2024 | Closurefast, Minimed 780g |
| Merck Sharp & Dohme LLC | $61.68 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $53.61 | 2023-2024 | Gemtesa |
| Ultragenyx Pharmaceutical INC. | $50.72 | 2022-2023 | |
| Pfizer INC. | $50.29 | 2019-2024 | |
| Amgen INC. | $44.59 | 2019-2024 | Evenity, Prolia |
| Vistapharm, INC. | $40.70 | 2021 | |
| Astellas Pharma US INC | $39.49 | 2024 | Xtandi |
| Endo Pharmaceuticals INC. | $38.73 | 2019-2023 | Aveed, Xiaflex |
| Amryt Pharma Holdings Ltd | $37.01 | 2023 | Mycapssa |
| Telix Pharmaceuticals | $36.30 | 2023-2024 | Illuccix |
| Insulet Corporation | $27.24 | 2019 | |
| Tandem Diabetes Care, INC. | $25.96 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Halozyme INC | $22.08 | 2023 | |
| Valeritas, INC. | $21.56 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.79 | 2020 | |
| Recordati_rare_diseases_inc. | $18.06 | 2023 | Isturisa, Signifor Lar |
| Janssen Biotech, INC. | $17.94 | 2019 | |
| Medtronic Minimed, INC. | $14.97 | 2019 | |
| Shire North American Group INC | $14.39 | 2019 | |
| Ibsa Pharma INC. | $13.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.